Grade of Adverse Event	1- Mild		2- Mod		3-Severe		4- LifeThr		5-Lethal		Total
	n	(%)	n	(%)	n	(%)	n	(%)	n	(%)	N
Non-Hematologic Adverse Events											
Eye disorders - Other, Specify	1	8%	0	0%	0	0%	0	0%	0	0%	12
General disorders and administration site conditions - Other, Specify	1	8%	0	0%	0	0%	0	0%	0	0%	12
<b>Endocrine disorders</b>											
Hyperthyroidism	0	0%	1	8%	0	0%	0	0%	0	0%	12
<b>Gastrointestinal disorders</b>											
Abdominal pain	1	8%	1	8%	0	0%	0	0%	0	0%	12
Constipation	1	8%	1	8%	0	0%	0	0%	0	0%	12
Diarrhea	1	8%	2	17%	0	0%	0	0%	0	0%	12
Rectal hemorrhage	1	8%	0	0%	0	0%	0	0%	0	0%	12
General disorders and administration	n site	conditio	ons								
Fatigue	0	0%	1	8%	0	0%	0	0%	0	0%	12
Fever	2	17%	0	0%	0	0%	0	0%	0	0%	12
Flu like symptoms	1	8%	0	0%	0	0%	0	0%	0	0%	12
Injection site reaction	3	25%	0	0%	0	0%	0	0%	0	0%	12
Pain	2	17%	0	0%	0	0%	0	0%	0	0%	12
Infections and infestations											
Mucosal infection	0	0%	1	8%	0	0%	0	0%	0	0%	12
Skin infection	1	8%	0	0%	0	0%	0	0%	0	0%	12
Upper respiratory infection	1	8%	0	0%	0	0%	0	0%	0	0%	12
Investigations											
Blood bilirubin increased	1	8%	0	0%	0	0%	0	0%	0	0%	12
Musculoskeletal and connective tissue	e diso	rders									
Arthralgia	1	8%	0	0%	0	0%	0	0%	0	0%	12
Nervous system disorders											
Headache	0	0%	1	8%	0	0%	0	0%	0	0%	12
Respiratory, thoracic, and mediastina	al disc	orders									
Cough	2	8%	0	0%	0	0%	0	0%	0	0%	12
Pleuritic pain	1	8%	0	0%	0	0%	0	0%	0	0%	12
Skin and subcutaneous tissue disorde	ers										
Scalp pain	0	0%	1	8%	0	0%	0	0%	0	0%	12
Summary		1					ı				
Maximum Non-Hematologic AE	6	50%	5	42%	0	0%	0	0%	0	0%	12
Maximum Overall AE	6	50%	5	42%	0	0%	0	0%	0	0%	12